Mild Cognitive Impairment (MCI), Sarcopenia
Conditions
Keywords
Tai Chi, Cognitive Function
Brief summary
Mild Cognitive Impairment (MCI) in older adults is linked to muscle loss (sarcopenia) and can lead to dementia, with pain further impacting cognitive and physical performance. Tai Chi, a mind-body exercise, is recommended for managing MCI as it supports cognitive function, mood, and physical health. The investigators' first goal is to characterize the correlation of heart rate variability and cortical activity on cognitive function and the psychosocial correlates of pain interference and social isolation on cognitive function at baseline and post-intervention (8 weeks of Tai Chi). The second goal is to explain the role of sarcopenia and obesity in the relationship between pain interference and cognitive function. The investigators also want to examine the index of the predictive capacity regarding sarcopenia and obesity on cognitive function outcomes.
Interventions
BEHAVIORALTai Chi
The Tai Chi program content is based on the Harvard Medical School (HMS) Guide to Tai Chi, developed by clinical scientist Dr. Peter M. Wayne. Each participant will receive a workbook that describes the philosophy, evidence, and practice of Tai Chi, along with a video series for home practice that features the exercises from the HMS Guide to Tai Chi program. The in-person classes will be led by the PI and delivered weekly over 8 weeks, with 75-minute sessions. The in-person and video series will include an introduction to the principles of practice and tips on establishing and maintaining a practice, followed by a series of warm-up exercises, Tai Chi movements, and cool-down exercises. The Tin-person (and offer virtual live sessions for those who cannot attend in-person) over 8 weeks, accompanied by a workbook and video-recorded practices to promote self-management.
Sponsors
Ohio University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Participants who are older adults, defined as ≥60 years old. 2. Participants must have the ability to independently stand without the use of an assistive device for 20 minutes. 3. People with Mild Cognitive Impairment (MCI) (initial cohort) and without MCI (age-gender matched healthy controls). A score of between \>18 and ≤26 on the Montreal Cognitive Assessment (MoCA) will be used to classify MCI. A score above 26 is considered normal.
Exclusion criteria
1. Participants with significant uncontrolled medication, and cardiovascular, respiratory, and metabolic symptoms will be excluded from participation in the study, as these symptoms could impact their engagement with the engagement of Tai Chi. 2. Investigators will administer a brief screening questionnaire to assess (a) hypotension symptoms related to intensive treatment of hypertension and (b) hypoglycemia related to intensive treatment of diabetes, as these conditions are associated with cognitive decline. 3. Investigators will capture data on potential sleep apnea and administer the Stop-Bang Questionnaire to identify potential sleep-disordered breathing. Participants with significant uncontrolled sleep apnea will be excluded as this could also impact their engagement in the intervention and influence the primary outcome measure of cognitive function. 2\. Currently or recently practicing Tai Chi. Participants will be excluded if they are currently practicing Tai Chi. If participants have previously engaged in Tai Chi, there will be a washout period of at least 6 months before considering enrollment in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Executive Function - Stroop Color-Word Interference Test | From enrollment to the end of treatment at 8 weeks | Delis-Kaplan Executive Function System Stroop Color-Word Interference Test |
| Executive Function - Semantic Fluency Test | From enrollment to the end of treatment at 8 weeks | Repeatable Battery for the Assessment of Neuropsychological Status - Semantic Fluency Test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive Function - Processing Speed | From enrollment to the end of treatment at 8 weeks | Repeatable Battery for the Assessment of Neuropsychological Status Coding Test |
| Pain Interference | From enrollment to the end of treatment at 8 weeks | Patient Reported Outcome Measurement Information System (PROMIS) - Pain Interference Item Bank |
| Social Isolation | From enrollment to the end of treatment at 8 weeks | Patient Reported Outcome Measurement Information System (PROMIS) Social Isolation Item Bank |
| Positive Affect | From enrollment to the end of treatment at 8 weeks | Patient Reported Outcome Measurement Information System (PROMIS) Positive Affect Item Bank |
| Meaning and Purpose | From enrollment to the end of treatment at 8 weeks | Patient Reported Outcome Measurement Information System (PROMIS) Meaning and Purpose Item bank |
| Heart Rate Variability | From enrollment to the end of treatment at 8 weeks | Heart Rate Variability recorded while sitting for 5 minutes using a photoplethysmogram. |
| Cortical activity | From enrollment to the end of treatment at 8 weeks | Cortical activity will be recorded during a brief Tai Chi Practice before and after the 8-week Tai Chi intervention using a functional Near Infrared Spectroscopy system. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Physical Performance Test Battery for Sarcopenia (1 of 6) | From enrollment to the end of treatment at 8 weeks | (1) Hand Grip Strength using a JAMAR® dynamometer, adjusted to fit participants' hands as described elsewhere. A minimum of three trials with 60 seconds of rest between trials, and additional trials if the highest two values differ by more than 3 kg. Unit: Force in kilograms The investigators will diagnose sarcopenia using the European Working Group's (EWGSOP2) revised consensus definition, which involves assessing two measures and current sarcopenia reference values: (i) hand grip strength via dynamometry and (ii) gait speed. |
| Body Mass Index | From enrollment only | Body Mass Index (BMI) will be assessed to identify the moderating role of obesity on pain interference and executive function. Weight and height will be combined to report BMI in kg/m\^2). |
| Physical Performance Test Battery for Sarcopenia (2 of 6) | From enrollment to the end of treatment at 8 weeks | (2) Usual Gait Speed over 4 meters to assess for gait speed. Unit: Seconds The investigators will diagnose sarcopenia using the European Working Group's (EWGSOP2) revised consensus definition, which involves assessing two measures and current sarcopenia reference values: (i) hand grip strength via dynamometry and (ii) gait speed. |
| Physical Performance Test Battery for Sarcopenia (3 of 6) | From enrollment to the end of treatment at 8 weeks | (3) Six Minute Walk Test to assess for submaximal aerobic walking capacity. Unit: Meters |
| Physical Performance Test Battery for Sarcopenia (4 of 6) | From enrollment to the end of treatment at 8 weeks | (4) Four-Square Step Test to assess for dynamic balance that involves stepping over objects forward, sideways, and backward. Unit: Seconds |
| Physical Performance Test Battery for Sarcopenia (5 of 6) | From enrollment to the end of treatment at 8 weeks | (5) 5x Repeated Sit-to-Stand Test to assess lower extremity strength. Unit: Seconds |
| Physical Performance Test Battery for Sarcopenia (6 of 6) | From enrollment to the end of treatment at 8 weeks | (6) Stair Climb Power Test to assess lower extremity power. Unit: Seconds. |
| Cognitive Assessment Screen | From enrollment only | Montreal Cognitive Assessment used as a screening tool which measures short term memory, visuospatial abilities, executive functions, attention, concentration and working memory, and language orientation to time and place. |
Countries
United States
Contacts
Primary ContactNicholas Karayannis, MPT, PhD
Outcome results
None listed